Go To patient/caregiver site Go to healthcare provider site

Anaphylaxis is on the rise1-3

Get information and data about
life-threatening allergies.

The number of anaphylactic events in the United States has risen in recent years, including among infants and toddlers.1-3

It is estimated that about 6 million children have food allergies.4,5

Asset 1

Hospitalizations from anaphylaxis rose from 21.0 to 25.1 per million population between 1999 and 2009.1

Asset 171999200925.1 per million21.0 per million

Hospitalizations from anaphylaxis

Food-related allergic emergencies send someone to the hospital on average every 3 minutes.6,7

Asset 15

Emergency department visits for anaphylaxis among children (< 21 years old) in the US increased 3X between 2008 and 2016.8

Where will your patient be when anaphylaxis occurs?

Allergic emergencies can happen outside the comfort and familiarity of home, in places like9-13:

Asset 10


Asset 11


Asset 12


Asset 13


People with little or no prior training may be called upon to administer epinephrine.11,14,15

According to a survey of 2040 school nurses, staff that may be allowed to administer epinephrine include14:

Asset 4


Asset 5


Asset 6


Asset 7


Asset 8


Asset 9


Immediate treatment with epinephrine is the standard of care for anaphylaxis16-18

Delayed epinephrine administration in anaphylaxis is associated with an increased risk of hospitalization and poor outcomes including death.13,18-21

What might stop your patients from using their epinephrine auto-injector during anaphylaxis?

Asset 2

A Canadian study of 965 cases of anaphylaxis (median age 5.8 years) showed only 51% of patients who had an epinephrine auto-injector used it before arrival to the emergency department.22

Discover the features of AUVI-Q® (epinephrine injection, USP) to see how it fits in the lives of your patients with life-threatening allergies.


Sign up for updates from AUVI-Q.


Innovative voice instructions

Discover the epinephrine auto-injector that
was designed to be easy to use.

AUVI-Q features a voice-instruction system to guide users step by step through an injection.23 It even reminds the patient to call 911.

Asset 2

were able to complete a simulated injection with AUVI-Q on the first attempt.19

100% of adults aged 16-55 years (n=20) and 95% of pediatric patients aged 7-15 years (n=20) were able to complete a simulated injection with AUVI-Q on the first attempt in a design validation and labeling comprehension study, without committing a critical use error or receiving any training from a healthcare practitioner.24

In a simulated use study scenario, participants (n=693) were 2x more likely to correctly complete all the steps of the injection protocol with AUVI-Q vs Epipen® (epinephrine injection, USP).25

Asset 1

Voice instructions give users, whether trained or not, step-by-step guidance for completing an injection.23

Prompt administration of epinephrine is key to treating life-threatening anaphylaxis.16-18 Ease of use may help your patients when it counts.


AUVI-Q was designed with size in mind, and is about the size of a credit card and thickness of a cell phone.

Asset 2

Are your patients among those who fail to carry their epinephrine with them at all times?12,15,26

In a study of 693 participants, AUVI-Q was significantly (P<0.001) preferred over EpiPen® (epinephrine injection, USP) in 2 key measures.25

Visit the AUVI-Q patient site to watch patients describe their own preferences.

Auto-retractable needle

Take a closer look at the first and only epinephrine auto-injector with an automatic needle retraction system.23

With the auto-retractable needle epinephrine is delivered in less than half a second. However, users must push firmly and hold for a complete 2-second count.23

Only with AUVI-Q:

  • The auto-retractable needle is not visible before, during, or after an injection.23
  • Patients may not feel the injection when it occurs.23

Minimizing the risk of injection-related injury

When administering AUVI-Q to young children and infants, hold the child’s leg firmly in place and limit movement prior to and during injection.23

Purposeful design

AUVI-Q was designed to make clear which end houses the needle to address safety concerns associated with epinephrine auto-injectors, like accidental digit injections.27

AUVI-Q administration in 3 steps23

Watch a simulated injection of AUVI-Q:

After use, instruct patient to get emergency medical help right away.

To minimize the risk of injection-related injury, instruct caregiver to hold a young child’s or infant’s leg firmly in place when administering AUVI-Q.23



AUVI-Q is available in 3 strengths

AUVI-q 0.1 mg

For infants and toddlers weighing 16.5 lbs to 33 lbs.

AUVI-Q 0.15 mg

For children weighing 33 lbs to 66 lbs.

AUVI-Q 0.3 mg

For anyone who weighs 66 lbs or more.

With the rate of anaphylactic events on the rise in young children, it’s important to make sure pediatric patients in your practice have the epinephrine they need.2,5,8,28,29

AUVI-q 0.1 mg is the first and only FDA-approved epinephrine auto-injector designed specifically for infants and toddlers weighing 16.5 lbs to 33 lbs.23

Shortest needle length (7.4 mm)

The shortest available needle among epinephrine auto-injectors that helps deliver the dose at the right depth.

Quick injection

Though users must press and hold for 2 seconds, the injection is completed in less than a second.

AUVI-q 0.1 mg was designed with the same easy-to-use features as the rest of the product family.

Take a look at a simulated injection with the AUVI-q 0.1 mg dose.

To minimize the risk of injection-related injury, instruct caregiver to hold a young child’s or infant’s leg firmly in place when administering AUVI-Q.23


Every AUVI-Q is manufactured according to the highest standards.

How it's made:

  • Manufactured on an intelligent, high-tech, 100% automated robotic production line
  • Over 100 automated quality checks are performed on each AUVI-Q device
  • Specially calibrated sensors and vision inspection systems help ensure each component is assembled with precision
  • Identifiers are used to track individual components throughout the build

This process helps produce a consistent, high-quality product.

Developed by Patients, for Patients®

AUVI-Q was developed by twin brothers who grew up with life-threatening allergies and made it their mission to bring innovation to the epinephrine auto-injector market.

See first-hand accounts of how AUVI-Q affects the lives of those who use it by visiting the AUVI-Q patient site.

Is AUVI-Q a good fit for your practice?


Sign up for updates from AUVI-Q.


e-prescription details

Learn about patient access
and how to e-prescribe AUVI-Q.

If you’ve decided AUVI-Q is right for your commercially insured patients, e-prescribing is simple in your EMR.*

Choose home delivery with the AUVI-Q direct delivery service or send the prescription to Walgreens for in-store pickup. Find more details about each option below.


    (mail order pharmacy) to have AUVI-Q delivered to your patient’s door.

    in the EMR notes section, including:

    • Specific life-threatining allergies
    • Patient weight
    • Other treatments tried, start date, and duration

    the AUVI-Q direct delivery service will call or text your patient to schedule delivery of their AUVI-Q. Patients can call 1-844-357-3968 to check on the status of their prescription.


    For in-store pickup

    Let your patients know that they can search for a Walgreens near them for in-store pickup.


If they have further questions, direct them to our FAQs.

*If you don’t have an EMR system, complete the direct delivery system enrollment form and fax it to 1-877-397-7479, OR, instruct patients to bring their prescription to Walgreens for in-store pickup.

Call 1-877-30-AUVIQ for assistance

Patient access

Eligible patients with commercial insurance pay $0 out of pocket for their AUVI-Q*

$0 out of pocket

Eligible patients will receive up to 2 cartons of AUVI-Q for $0 out of pocket each year.


Kaléo Cares Patient Assistance

Those without government or commercial insurance who cannot afford their medicines may qualify for support through the kaléo Cares Patient Assistance Program.


Sign up for updates from AUVI-Q.



Find educational information about AUVI-Q
for your patients, staff, and practice.

AUVI-Q® (epinephrine injection, USP) is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to allergens, idiopathic and exercise-induced anaphylaxis. AUVI-Q is intended for patients with a history of anaphylactic reactions or who are at increased risk for anaphylaxis.

Important Safety Information

AUVI-Q is intended for immediate self-administration as emergency supportive therapy only and is not a substitute for immediate medical care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. Each AUVI-Q contains a single dose of epinephrine for single-use injection. More than two sequential doses of epinephrine should only be administered under direct medical supervision. Since the doses of epinephrine delivered from AUVI-Q are fixed, consider using other forms of injectable epinephrine if doses lower than 0.1 mg are deemed necessary.

AUVI-Q should ONLY be injected into the anterolateral aspect of the thigh. Do not inject intravenously, or into buttock, digits, hands, or feet. Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.

Epinephrine should be administered with caution to patients with certain heart diseases, and in patients who are on medications that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported in patients with underlying cardiac disease or taking cardiac glycosides or diuretics. Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Please see the full Prescribing Information and the Patient Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.